Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response

Plain-language summary

This study aimed to examine a genomic signature that could predict response to therapy in patients with multiple sclerosis. It enrolled people aged 18 and older living in the United States with internet access who self-reported a multiple sclerosis diagnosis. The trial was a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

DxTerity Diagnostics

Start date

11/7/2017

Estimated completion

2/25/2020

Countries

United States

Related genes

Locations

• Compton, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male and female patients age 18 or older
* Have a permanent address in the United States for the duration of the study
* Have an email address and access to the internet for the duration of the study
* Able to provide informed consent
* Self-reported diagnosis of MS

Exclusion Criteria:

* None